INHIBITION OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM BY L-DOPA WITH AND WITHOUT INHIBITION OF EXTRA-CEREBRAL DOPA DECARBOXYLASE IN MAN

被引:7
作者
BARBIERI, C [1 ]
CALDARA, R [1 ]
FERRARI, C [1 ]
CROSSIGNANI, RM [1 ]
RECCHIA, M [1 ]
机构
[1] IST RIC FARMACOL, BIOMETR UNIT, MILAN, ITALY
关键词
D O I
10.1042/cs0610187
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The possibility was studied that CNS mono-aminergic pathways may play a role in the control of the renin-angiotensin-aldosterone system in man. Eight normal subjects received in a randomized order placebo, L-dopa (500 mg, orally) and L-dopa (100 mg, orally) plus carbidopa (35 mg, orally) after pretreatment with carbidopa (50 mg every 6 h for 4 doses). L-Dopa administration elicited a significant fall in plasma renin activity (PRA) (P < 0.01 at 120, 150 and 180 min) and in plasma aldosterone levels (P < 0.05 at 90, 120, 150 and 180 min); L-dopa plus carbidopa induced a decrease in PRA (P < 0.05 at 120 and 150 min, P < 0.01 at 180 min) and in plasma aldosterone concentration (P < 0.05 at 30 and 60 min, P < 0.01 at 90 and 120 min), in comparison with placebo administration; between-drugs analysis revealed no difference in the decreases in PRA and plasma aldosterone levels induced by the 2 regimens. As L-dopa, and L-dopa plus carbidopa, augments catecholamine levels in the brain of various animal species, the present data suggest that in man PRA and plasma aldosterone concentration might be inhibited by increased CNS catecholamine levels.
引用
收藏
页码:187 / 190
页数:4
相关论文
共 25 条
[1]   RENIN-ALDOSTERONE SYSTEM IN PARKINSONS DISEASE [J].
BARBEAU, A ;
GILLOJOF.L ;
BOUCHER, R ;
NOWACZYNSKI, W ;
GENEST, J .
SCIENCE, 1969, 165 (3890) :291-+
[2]   GROWTH-HORMONE SECRETION IN HYPERTENSIVE PATIENTS - EVIDENCE FOR A DERANGEMENT IN CENTRAL ADRENERGIC-FUNCTION [J].
BARBIERI, C ;
FERRARI, C ;
CALDARA, R ;
CURTARELLI, G .
CLINICAL SCIENCE, 1980, 58 (02) :135-138
[3]   DECREASE OF CEREBRAL 5-HYDROXYTRYPTAMINE BY 3,4-DIHYDROXYPHENYLALANINE AFTER INHIBITION OF EXTRACEREBRAL DECARBOXYLASE [J].
BARTHOLINI, G ;
DAPRADA, M ;
PLETSCHER, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1968, 20 (03) :228-+
[4]   EFFECT OF VARIOUS DECARBOXYLASE INHIBITORS ON CEREBRAL METABOLISM OF DIHYDROXYPHENYLALANINE [J].
BARTHOLINI, G ;
PLETSCHER, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1969, 21 (05) :323-+
[5]  
BLAIR ML, 1977, J PHARMACOL EXP THER, V202, P209
[6]   EFFECTS OF METOCLOPRAMIDE AND BROMOCRIPTINE ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN MAN - DOPAMINERGIC CONTROL OF ALDOSTERONE [J].
CAREY, RM ;
THORNER, MO ;
ORTT, EM .
JOURNAL OF CLINICAL INVESTIGATION, 1979, 63 (04) :727-735
[7]   BLOOD-BRAIN BARRIER TO CARBIDOPA (MK-486) AND RO4-4602, PERIPHERAL DOPA DECARBOXYLASE INHIBITORS [J].
CLARK, WG ;
OLDENDORF, WH ;
DEWHURST, WG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1973, 25 (05) :416-418
[8]  
EDWARDS CRW, 1975, LANCET, V2, P903
[9]   APPLICATION OF A RADIOIMMUNOASSAY FOR ANGIOTENSIN I TO PHYSIOLOGIC MEASUREMENTS OF PLASMA RENIN ACTIVITY IN NORMAL HUMAN SUBJECTS [J].
HABER, E ;
KOERNER, T ;
PAGE, LB ;
KLIMAN, B ;
PURNODE, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1969, 29 (10) :1349-+
[10]   CENTRAL HYPOTENSIVE EFFECT OF L-3,4-DIHYDROXYPHENYLALANINE IN RAT [J].
HENNING, M ;
RUBENSON, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1970, 22 (08) :553-&